Timothy Rummel, MD
Pulmonary Disease · Colorado Springs, CONPI 1598760217
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,455 of the $7,768 with a category attached, or 70.2%. It is spread thinly across 38 manufacturers, the largest accounting for just 23.0%. 2025 is the largest year on record at $2,714, 4.9 times the $549 reported in 2019.
Across 249 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$2K
- Inspire Medical Systems, Inc.$1K
- AstraZeneca$906
- Harmony Biosciences LLC$717
- GSK$375
- Jazz Pharmaceuticals Inc.$336
- plus $2K from 32 others
Across 10 payments — averaging $10,036 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$99K
- GSK$2K
What the payments were for
- Speaking & faculty fees$1001%
- Travel & lodging$1,93525%
- Food & beverage$5,45570%
- Education$2774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 10 | $1,785 |
| Inspire Medical Systems, Inc. | 19 | $1,484 |
| AstraZeneca(2 entities) | 43 | $906 |
| Harmony Biosciences LLC | 19 | $717 |
| GSK | 37 | $375 |
| Jazz Pharmaceuticals Inc. | 14 | $336 |
| Grifols USA, LLC | 11 | $222 |
| United Therapeutics Corporation | 9 | $219 |
| Axsome Therapeutics, Inc. | 7 | $175 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $152 |
| Boehringer Ingelheim | 8 | $128 |
| Sanofi | 4 | $114 |
| Actelion Pharmaceuticals US, Inc. | 5 | $111 |
| Gilead | 5 | $99 |
| Lilly USA, LLC | 3 | $74 |
| Mylan Specialty L.p. | 4 | $74 |
| Amgen | 3 | $63 |
| Bayer | 3 | $60 |
| Insmed, Inc. | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 4 | $53 |
| AbbVie | 3 | $53 |
| Philips North America LLC | 3 | $47 |
| Genentech USA, Inc. | 3 | $46 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| Baxter Healthcare | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Resmed Corp | 2 | $34 |
| Merck | 2 | $34 |
| Novartis | 2 | $33 |
| Shire North American Group Inc | 2 | $32 |
| 3b Medical, Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $24 |
| GE HealthCare | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$1,631
- Inspire$989
How this compares
$7,768 in reported general payments places this provider in the 75th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ambrisentan | 31 | $45,014 |
| Spiriva RespimatTiotropium Bromide | 31 | $21,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,433 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $18,086 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $14,383 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $11,314 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,414 |
| Modafinil | 82 | $5,311 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $4,913 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,608 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,548 |
| Tadalafil | 13 | $1,414 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $654 |
| Temazepam | 11 | $639 |
| Olanzapine OdtOlanzapine | 14 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $128 | $47,49157 claims |
| GSKTrelegy Ellipta | $375 | $21,43325 claims |
| AstraZenecaSymbicort | $906 | $18,08654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Colorado Springs
- Christopher MerrickColorado Springs$34K
- Andrew BoulosColorado Springs$14K
- Lalith UragodaColorado Springs$12K
- Russell LeeColorado Springs$11K
- Dheeraj DhotreColorado Springs$9K
- Yogesh ShresthaColorado Springs$7K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.